24/7 Market News Snapshot 12 February, 2025 – Bio-Path Holdings Inc (NASDAQ:BPTH)

February 12, 2025

DENVER, Colo., 12 February, 2025 (247marketnews.com) – (NASDAQ:BPTH) are discussed in this article.
Bio-Path Holdings Inc (NASDAQ:BPTH), a leading biotechnology firm focusing on innovative therapies, is experiencing significant market momentum, with its stock opening at $0.721 and soaring by 34.59% to $1.035, driven by strong investor confidence. Trading volume reached 2.32 million shares, underscoring heightened interest in the company’s advancements in the biotech landscape.

This surge coincides with the company’s progress in its Phase 1/1b clinical trial evaluating BP1002 for refractory/relapsed acute myeloid leukemia (AML). The trial has successfully advanced to a fourth higher dose cohort of 90 mg/m², following promising responses in earlier cohorts. CEO Peter Nielsen commented on the encouraging developments, noting a significant reaction in a patient from the third cohort, who demonstrated stable disease and a notable reduction in blast count after just one treatment cycle. This is especially vital for patients resistant to venetoclax, who historically face bleak prognoses.

The rapid enrollment in the third dosing cohort reflects a strong demand for innovative treatment options in AML, a field with pressing needs. Bio-Path aims to expedite the ongoing study and explore combination therapies in subsequent trial phases. The proprietary DNAbilize® technology employed in BP1002 targets Bcl-2 at the mRNA level, potentially overcoming treatment resistance among AML patients and improving therapeutic efficacy.

As the Phase 1b segment prepares to initiate evaluations of BP1002 in conjunction with decitabine, leadership from esteemed cancer centers drives the study’s implementation. Bio-Path Holdings is committed to revolutionizing cancer treatment paradigms and improving patient outcomes through its cutting-edge research and therapeutic innovations. The company remains focused on addressing the urgent needs of vulnerable patient populations, marking a significant step forward in the fight against cancer.

Related news for (BPTH)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.